Michael Mitchell

Head, Global Communications at The Medicines Co.

Michael Mitchell

Michael Mitchell

Head, Global Communications at The Medicines Co.

Biography

Michael Mitchell is former Head-Investor Relations & Global Communications at The Medicines Co. Mr. Mitchell received an undergraduate degree from Providence College and an MBA from Rutgers State University of New Jersey.

Overview
RelSci Relationships

282

Number of Boards

1

Relationships
RelSci Relationships are individuals Michael Mitchell likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Rempex Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Executive Officer & Director at The Medicines Co.

Relationship likelihood: Strong

Chief Executive Officer at Innocrin Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Financial Officer & Treasurer at The Medicines Co.

Relationship likelihood: Strong

Executive Vice President, General Counsel & Secretary at The Medicines Co.

Relationship likelihood: Strong

Global Launch Leader, Anti-Platelet Solutions at The Medicines Co.

Relationship likelihood: Strong

Head, Global Contracting & Business Ethics at The Medicines Co.

Relationship likelihood: Strong

Co-Founder at The Medicines Co.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Ophthotech Corp.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Qpex Biopharma, Inc.

Relationship likelihood: Strong

Paths to Michael Mitchell
Potential Connections via
Relationship Science
You
Michael Mitchell
Head, Global Communications at The Medicines Co.
Education
Bachelor of Science Degree in Health Policy & Management
Master of Business Administration in Finance
Career History
Head, Global Communications
2002 - Current

The Medicines Co We are a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. In the United States, we have three marketed products, Angiomax® (bivalirudin) for Injection, Cleviprex® (clevidipine) Injectable Emulsion, and Argatroban Injection, 50 mg per 50 mL†. We also have a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. We believe that Angiomax, Cleviprex and our products in development possess favorable attributes that can satisfy unmet medical needs in the acute | intensive care hospital product market and offer, or, in the case of our products in development, have the potential to offer, improved performance to hospital businesses. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 425 professionals.

Professional
Prior

Daniel J. Edelman, Inc. provides public relations and strategic communication services. The firm's services include financial communications, investor relations, corporate affairs, diversity marketing, litigation, and public affairs. It provides services to the consumer, health, and technology industries. The company is headquartered in Chicago, IL.

Boards & Committees
Director
Prior
Other Affiliations

Michael Mitchell is affiliated with The Medicines Co., Edelman, Inc., Feinstein Kean Healthcare

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Michael Mitchell. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Michael Mitchell's profile does not indicate a business or promotional relationship of any kind between RelSci and Michael Mitchell.